Skip to main content
Enzymatic synthesis of aptamer-targeted polynucleotide drug delivery platforms for cancer therapy

Enzymatic synthesis of aptamer-targeted polynucleotide drug delivery platforms for cancer therapy

Unmet Need In the United States alone, over 1.8 million new patients were diagnosed with cancer in 2021, and over 600,000 patients died from the disease. Cytostatic nucleotides, such as gemcitabine and 5-fluorouracil, have been…

Read More

A class of biodegradable stealth polymers to improve drug delivery

A class of biodegradable stealth polymers to improve drug delivery

Unmet Need Delivery of drugs or therapeutics such as small molecules, peptides, and proteins, in their native form, is limited by their poor stability, low solubility, and short in vivo circulation. These challenges in drug…

Read More

A method for treating TRAIL-resistant cancers

A method for treating TRAIL-resistant cancers

Unmet Need Over the past twenty years, TNF-related apoptosis-inducing ligand (TRAIL) has been shown to kill a variety of human cancer cells in vitro and in vivo while remaining innocuous to healthy cells. Unfortunately, the…

Read More

A bio-based method for producing adipic acid by using an enzyme to selectively convert 2-oxoadipate to (R)-2-hydroxyadipate

A bio-based method for producing adipic acid by using an enzyme to selectively convert 2-oxoadipate to (R)-2-hydroxyadipate

Unmet Need Adipic acid (1,4-butanedicarboxylic acid; COOH(CH2)4COOH), is among the most-produced chemicals worldwide, with approximately 2.5 billion kilograms synthesized annually and a global market of 8 billion USD. The most typical use for adipic acid…

Read More

A fully human EGFRvIII-targeted bispecific antibody engaging T cells for antitumor therapy

A fully human EGFRvIII-targeted bispecific antibody engaging T cells for antitumor therapy

Value Proposition The most common malignant brain tumor, glioblastoma multiforme (GBM), remains uniformly fatal despite surgery, radiation, and chemotherapy. Conventional therapy for malignant glioma fails to specifically target tumor cells. In contrast, substantial evidence indicates…

Read More

Sublingual immunization using supramolecular peptide-polymer conjugate tablets

Sublingual immunization using supramolecular peptide-polymer conjugate tablets

Value proposition Immunization with vaccines prevent illness, disability, and currently avert an estimated 2 to 3 million deaths every year. However, commonly-used vaccine technology platforms can be unpredictable, require a high manufacturing cost, and often…

Read More

Increasing the half-life of therapeutic proteins and peptides using elastomeric-like polypeptides with environmental sensitivity

Increasing the half-life of therapeutic proteins and peptides using elastomeric-like polypeptides with environmental sensitivity

Value Proposition Since insulin was used as the first therapeutic protein in a clinical setting, the field of protein therapeutics has rapidly expanded. From 2014-2018, therapeutic proteins had the highest compound annual growth rate of…

Read More

Mining microbial genomes for biologically active compounds

Mining microbial genomes for biologically active compounds

Most microbes of importance to human and environmental health are not amenable to experimentation. As a result, we do not know what molecules these microbes use to manipulate their environment- many of which are likely…

Read More

A universal antidote for aptamer therapeutics

A universal antidote for aptamer therapeutics

Value Proposition With an ever increasing number of people taking numerous medications, the need to safely administer drugs and limit unintended side effects has never been greater. Antidote control remains the most direct means to…

Read More

Unstructured non-repetitive polypeptides as a tool for imparting temperature-dependent physical properties to protein fusions

Unstructured non-repetitive polypeptides as a tool for imparting temperature-dependent physical properties to protein fusions

Value Proposition Proteins can be useful therapeutic agents when engineered for specificity and selectivity for a clinical target. Their complexity, versatility, tolerability, and diversity often make them superior alternatives to small molecule drugs, and the…

Read More

An integrated hybrid biological-materials platform for portable production of biomacromolecules

An integrated hybrid biological-materials platform for portable production of biomacromolecules

Value Proposition Bacteria are a common host to produce diverse biologics, accounting for ~30% of biopharmaceuticals. The industrial synthesis of recombinant proteins using bacterial hosts entails multiple steps that each require a sophisticated and delicate…

Read More

Novel AnnexinA1 tripeptide (ANXA1sp) improves acute kidney injury after deep hypothermic circulatory arrest

Novel AnnexinA1 tripeptide (ANXA1sp) improves acute kidney injury after deep hypothermic circulatory arrest

Value Proposition Heart disease is the leading cause of death in industrialized nations across the world, with treatments often requiring surgery such as coronary artery bypass graft (CABG) or even transplantation. Although cardiac surgery is…

Read More

Have Questions?

Please contact us or subscribe for more opportunities

Stay in Touch with Us